1. Michael Marusich, Ph.D., mAbDx, and Carl Hauser, M.D., Harvard, awarded collaborative Mérieux Research Grant to identify and characterize new mtDAMPs that drive systemic inflammation after trauma

    Mon 01 July 2013

    mAbDx is pleased to announce that Michael Marusich, Ph.D., mAbDx, and Carl Hauser, M.D., Harvard, have been awarded a collaborative Mérieux Research Grant to identify new mitochondrial Damage Associated Molecular Patterns (mtDAMPs) that drive Systemic Inflammatory Response Syndrome (SIRS) after trauma.  Post-trauma SIRS is a common, potentially life-threatening ...

    read more
  2. University of Oregon and mAbDx finalize a License Agreement to develop and commercialize CTIP2 immunoassays as in vitro Diagnostic Licensed Products

    Thu 28 June 2012

    The University of Oregon and mAbDx have finalized a License Agreement to develop and commercialize CTIP2 immunoassays as in vitro Diagnostic Licensed Products.  CTIP2 (also known as BCL11b) is a zinc finger transcription factor essential for transcriptional control of hundreds of genes encoding key proteins in cell signaling pathways during ...

    read more
  3. mAbDx and MitoSciences/Abcam sign Master Project Agreement

    Tue 17 January 2012

    mAbDx and MitoSciences/Abcam sign Master Project Agreement for mAbDx to develop medical/clinical diagnostics for:  1) sepsis, 2) SIRS (Systemic Inflammatory Response Syndrome), 3) HNSCC (Head and Neck Squamous Cell Carcinoma), 4) preeclampsia, and 5) inherited diseases affecting mitochondrial OXPHOS complexes I and IV.

    read more

« Page 3 / 5 »